Syneos launches ‘reimagined FSP model for today’s customer challenges’

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/AndreyPopov)
(Image: Getty/AndreyPopov)

Related tags: Syneos Health, models, Service provider, Service, end-to-end, Pharmacovigilance

Syneos Health this week unveiled FSP 360, combining the company’s functional service provider experience with its end-to-end capabilities, says EVP.

According to the company, FSP 360 combines traditional service functions, like monitoring, project management, pharmacovigilance, and data services, with less-traditional capabilities, such as investigator payments, eTMF, site contracts, feasibility, and study startup.

"By pairing our 20 years of experience in the FSP space with our end-to-end capabilities - the broadest in the industry - we were able to purpose-built a reimagined FSP model for today’s customer challenges,”​ said Eleanore Doyle, Executive Vice President, FSP 360.

“The flexible model benefits from the experience we’ve gained through establishing 70 partnerships in 53 countries and our global footprint,”​ said Doyle, who will be leading FSP 360 with support from more than 4,5000 dedicated personnel globally.

The new model is a hybrid solution that can stand alone or be used in combination with full-service outsourcing, according to Syneos.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars